Pharmanutra Sustainability Profile
Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.
DitchCarbon Score
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmanutra's score of 33 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmanutra's reported carbon emissions
In 2023, Pharmanutra reported total carbon emissions of approximately 1,188,014 kg CO2e. This figure includes 229,189 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources. Scope 2 emissions, primarily from purchased electricity, amounted to about 270,515 kg CO2e (market-based), while Scope 3 emissions, which include indirect emissions from business travel and employee commuting, contributed significantly with 684,328 kg CO2e and 86,782 kg CO2e, respectively. Comparatively, in 2022, Pharmanutra's emissions were lower, with total emissions of about 275,843 kg CO2e, comprising 199,150 kg CO2e from Scope 1 and 57,666 kg CO2e from Scope 2. The company has shown a commitment to monitoring and reporting its emissions, although no specific reduction targets or initiatives have been documented as part of its climate strategy. Pharmanutra's emissions data is not cascaded from any parent organization, indicating that the figures are independently reported. The company continues to engage in sustainability practices, although further details on specific climate pledges or reduction initiatives are currently unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 39.72 | 00,000 | 00,000 | 000,000 |
| Scope 3 | - | - | - | 000,000 |
How Carbon Intensive is Pharmanutra's Industry?
How Carbon Intensive is Pharmanutra's Location?
Pharmanutra's Scope 3 Categories Breakdown
Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 61% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 89% of Scope 3 emissions.
Top Scope 3 Categories
Pharmanutra's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmanutra has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
